PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)

NCT01056172 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

164

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: Peginterferon alfa-2a and Ribavirin
DRUG: Peginterferon alfa-2a and Ribavirin

Sponsor

Pusan National University Yangsan Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]